No

Vaccine, Live Virus

Simultaneous immunization against measles and rubella

C

Immune deficiency condition, pregnancy

Immunocompromised persons, history of anaphylactic reaction following receipt of neomycin

All serious adverse reactions must be reported to the U.S. Department of Health and Human Services (DHHS) Vaccine Adverse Event Reporting System (VAERS) 1-800-822-7967.

Cardiovascular: Edema

Central nervous system: Fever (<100°F)

Local: Burning or stinging, induration

1% to 10%:

Central nervous system: Fever between 100°F and 103°F usually between 5th and 12th days postvaccination

Dermatologic: Rash (rarely generalized)

<1%: Fatigue, convulsions, encephalitis, confusion, severe headache, fever (>103°F - prolonged), palsies, Guillain-Barré syndrome, ataxia, urticaria, itching, reddening of skin (especially around ears and eyes), erythema multiforme, vomiting, sore throat, diarrhea, thrombocytopenic purpura, diplopia, stiff neck, dyspnea, cough, rhinitis, lymphadenopathy, coryza, allergic reactions

Whole blood, interferon immune globulin, radiation therapy, and immunosuppressive drugs (eg, corticosteroids) may result in insufficient response to immunization. DTP, OPV, MMR, Hib, and hepatitis B may be given concurrently; other virus vaccine administration should be separated by greater than or equal to 1 month from measles.

Refrigerate prior to use, use as soon as possible; discard if not used within 8 hours of reconstitution

Promotes active immunity to measles and rubella by inducing specific antibodies including measles-specific IgG and IgM and rubella hemagglutination-inhibiting antibodies.

Children at 15 months and Adults: S.C.: Inject 0.5 mL into outer aspect of upper arm; no routine booster for rubella

Not for I.V. administration

May temporarily depress tuberculin skin test sensitivity and reduce the seroconversion.

No information available to require special precautions

No effects or complications reported

Parents should monitor children closely for fever 5-11 days after vaccination; females should not become pregnant within 3 months of vaccination

Federal law requires that the date of administration, the vaccine manufacturer, lot number of vaccine, and the administering person's name, title and address be entered into the patient's permanent medical record

Injection: 1000 TCID₅₀ each of live attenuated measles virus vaccine and live rubella virus vaccine

Gardner P and Schaffner W, "Immunization of Adults," N Engl J Med, 1993, 328(17):1252-8.